Asad Haider, an analyst from Goldman Sachs, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The associated price target remains the same with $176.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Asad Haider has given his Buy rating due to a combination of factors that highlight Johnson & Johnson’s strong market position and growth potential. The recent Digestive Disease Week showcased JNJ’s advancements, particularly with Tremfya, which is gaining traction in the Inflammatory Bowel Disease (IBD) market. The product’s rapid growth in ulcerative colitis and its favorable reception by key opinion leaders (KOLs) underscore its commercial success.
Furthermore, the subcutaneous administration of Tremfya is seen as a significant advantage, facilitating quicker patient onboarding and streamlining office workflows. The lack of payor resistance and the potential for patient switches from other treatments to Tremfya further bolster its market prospects. Additionally, JNJ’s strong performance in the first quarter of 2025, where Tremfya exceeded consensus expectations, reinforces the positive outlook for the company’s pharmaceutical franchise.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $181.00 price target.
JNJ’s price has also changed slightly for the past six months – from $153.240 to $148.440, which is a -3.13% drop .